Validation of Gelsolin as a Biomarker
Author Information
Author(s): Haverland Nicole, Pottiez Gwënaël, Wiederin Jayme, Ciborowski Pawel
Primary Institution: University of Nebraska Medical Center
Hypothesis
If gelsolin is validated, it may become a candidate as a diagnostic biomarker.
Conclusion
Orthogonal validation using specific antibodies may lead to misleading results in biomarker studies.
Supporting Evidence
- Immunoreactivity of gelsolin varied greatly between different antibodies.
- Multiple forms of gelsolin were identified in the samples.
- Validation methods like Western blot may not accurately reflect the levels of gelsolin.
Takeaway
This study shows that using different antibodies can give different results when testing for gelsolin, which is important for finding reliable disease markers.
Methodology
Samples from human and monkey plasma and CSF were analyzed using Western blot and mass spectrometry.
Potential Biases
Different antibodies may yield inconsistent results, leading to potential bias in biomarker validation.
Limitations
The study faced challenges in validating gelsolin due to variability in antibody performance and the presence of multiple gelsolin forms.
Participant Demographics
Samples were classified based on neurocognitive status without other demographic criteria.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website